HCST and neoplasm: While efficacy of both NKG2D-CD3ζ and NKG2D-CD3ζ/Dap10 was poor, sustained tumor control was observed in 6/11 NKG2D/Dap10-12+ T cell-treated mice (Figure 3G) accompanied by increased survival (Figure 3H).